PlainRecalls
FDA Drug Moderate Class II Terminated

Ranitidine Tablets, USP 150 mg , a). 4 count bottle (NDC 70934-017-04), b). 20-count bottle (NDC 70934-017-20), c). 24-count bottle (NDC 70934-017-24) d). 30-count bottle (NDC 70934-017-30) e). 90-count bottle (NDC 70934-017-90), Rx Only, Repackaged by: Northwind Pharmaceuticals North Brenheim, NY 12131.

Reported: January 29, 2020 Initiated: December 20, 2019 #D-0794-2020

Product Description

Ranitidine Tablets, USP 150 mg , a). 4 count bottle (NDC 70934-017-04), b). 20-count bottle (NDC 70934-017-20), c). 24-count bottle (NDC 70934-017-24) d). 30-count bottle (NDC 70934-017-30) e). 90-count bottle (NDC 70934-017-90), Rx Only, Repackaged by: Northwind Pharmaceuticals North Brenheim, NY 12131.

Reason for Recall

CGMP Deviations: Presence of NDMA impurity detected in product.

Details

Recalling Firm
Denton Pharma, Inc.
Units Affected
1,341 bottles
Distribution
Nationwide
Location
North Blenheim, NY

Frequently Asked Questions

What product was recalled?
Ranitidine Tablets, USP 150 mg , a). 4 count bottle (NDC 70934-017-04), b). 20-count bottle (NDC 70934-017-20), c). 24-count bottle (NDC 70934-017-24) d). 30-count bottle (NDC 70934-017-30) e). 90-count bottle (NDC 70934-017-90), Rx Only, Repackaged by: Northwind Pharmaceuticals North Brenheim, NY 12131.. Recalled by Denton Pharma, Inc.. Units affected: 1,341 bottles.
Why was this product recalled?
CGMP Deviations: Presence of NDMA impurity detected in product.
Which agency issued this recall?
This recall was issued by the FDA Drug on January 29, 2020. Severity: Moderate. Recall number: D-0794-2020.